Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
39.41
+0.04 (0.10%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Immunovant Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, Immunovant stock has a consensus rating of "Buy" and an average price target of $47.53. The average 1-year stock price forecast is 20.60% higher than the current stock price, while the lowest is $24 (-39.10%) and the highest is $66 (+67.47%).
Price Target: $47.53 (+20.60%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Immunovant stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 4 | 5 | 5 | 5 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 18 | 18 | 18 | 18 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Reiterates $53 | Buy | Reiterates | $53 | +34.48% | Jul 9, 2026 |
| Citi | Citi | Buy Maintains $57 → $61 | Buy | Maintains | $57 → $61 | +54.78% | Jun 30, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $66 | Buy | Maintains | $66 | +67.47% | May 29, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $35 → $47 | Buy | Maintains | $35 → $47 | +19.26% | May 26, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $44 → $62 | Buy | Maintains | $44 → $62 | +57.32% | May 26, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
40.20M
EPS This Year
-2.44
from -2.47
EPS Next Year
-2.05
from -2.44
EPS and Forward PE are based on non-GAAP adjusted numbers.